Becton Dickinson and Company (NYSE: BDX) — Perfil da empresa, notícias e dados financeiros
Becton Dickinson specializes in medical technology, focusing on diagnostics and improving healthcare delivery.
Becton Dickinson and Company
Becton Dickinson and Company is a global medical technology company that develops, manufactures, and supplies medical devices, laboratory equipment, diagnostic products, and clinical systems. Headquartered in Franklin Lakes, New Jersey, the enterprise operates through three main business segments: BD Medical, BD Life Sciences, and BD Interventional. Its offerings encompass medication management and delivery solutions, vascular access technology, automated dispensing units, diagnostic specimen collection, molecular testing platforms, flow cytometry instruments, surgical meshes, and peripheral vascular intervention devices. The company serves healthcare institutions, clinical laboratories, pharmaceutical companies, research organizations, and life science practitioners worldwide.
Resumo
Operações
Produtos e/ou serviços de Becton Dickinson and Company
- Medication Delivery & Vascular Access: Hypodermic needles, syringes, intravenous catheters, vascular access devices, and continuous infusion systems designed for controlled drug administration, fluid therapy, and clinician safety across hospital and ambulatory care settings.
- Automated Dispensing & Medication Management: Automated medication dispensing cabinets, pharmacy robotics, preparation software, and clinical workflows that automate drug storage, dose preparation, inventory tracking, and administration verification in acute and long-term care facilities.
- Diagnostic & Specimen Management: Specimen collection devices, vacuum blood tubes, automated blood culture platforms, molecular diagnostic systems, and microbiology screening tools used by clinical laboratories for rapid pathogen identification and diagnostic testing.
- Biosciences & Cytometry Instruments: Flow cytometers, cell sorters, cell analysis systems, monoclonal antibodies, and standardized reagent kits utilized by academic, government, research, and clinical laboratories for high-dimensional cellular analysis and advanced immunology research.
- Reconstructive Surgery & Biosurgery Solutions: Synthetic and tissue-based surgical meshes, mechanical fixation systems, bioresorbable matrices, and biosurgery products utilized by surgeons in abdominal wall reconstruction, hernia repair, and specialized soft tissue procedures.
- Peripheral Intervention & Vascular Surgery: Endovascular catheters, peripheral balloon angioplasty systems, vascular stents, hemodialysis access devices, and targeted venous technology products used by interventional radiologists and vascular surgeons to treat peripheral arterial and venous diseases.
equipe executiva do Becton Dickinson and Company
- Thomas E. Polen Jr.President, CEO & Chairman
- Michael C. FeldExecutive VP & Chief Revenue Officer
- Vitor RoqueExecutive VP & CFO
- Elizabeth McCombsExecutive VP & CTO
- Joseph M. SmithSenior VP & Chief Scientific Officer
- Arthur HuExecutive VP and Chief Information & Digital Officer
- Shawn C. BevecSenior Vice President of Investor Relations
- Lanesha T. MinnixExecutive VP & General Counsel
- Carla BurigattoSenior VP & Chief Communications Officer
- Meera GopalakrishnanSenior VP & Global Chief Marketing Officer
Últimas notícias sobre a Becton Dickinson and Company
Principais indicadores financeiros
Resultados divulgados pela Becton Dickinson and Company, em USD.
- Cap. de mercado
- 53,1 bi
- Receita (TTM)
- 22,5 bi
- P/L
- 45.4
- LPA (diluído, TTM)
- 4.3
- Dividend yield
- 2.1%
- Margem de lucro
- 4.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 21,8 bi | 2,6 bi | 1,7 bi | |
| 20,2 bi | 2,4 bi | 1,7 bi | |
| 19,4 bi | 2,1 bi | 1,5 bi | |
| 18,9 bi | 2,3 bi | 1,8 bi |